BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 17, 2025
See today's BioWorld Asia
Home
» Bayer buys into China’s lucrative TCM market
To read the full story,
subscribe
or
sign in
.
Bayer buys into China’s lucrative TCM market
March 5, 2014
By
Shannon Ellis
SHANGHAI – Bayer AG is buying Dihon Pharmaceutical Group Co. located China’s southwest Yunnan province. Privately held Dihon makes OTC and traditional Chinese medicines (TCM) sold in China and Southeast Asia.
BioWorld Asia